Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
Radiopharm Theranostics announced positive Phase 2b trial results for RAD101, a novel PET imaging agent targeting fatty acid synthase, demonstrating 93% concordance with MRI and 86% sensitivity in detecting recurrent brain metastases. The company plans to initiate a US Phase 3 pivotal trial in Q4 2026, addressing a significant unmet need in neuro-o…